Shares of Novavax, Inc. (NASDAQ:NVAX) ended Monday session in green amid volatile trading. The shares closed up +0.39 points or 5.01% at $8.18 with 8.98 million shares getting traded. Post opening the session at $8.00, the shares hit an intraday low of $7.80 and an intraday high of $8.18 and the price vacillated in this range throughout the day. The company has a market cap of $2.30 billion and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) on Aug. 09, 2016 announced its financial results for the second quarter and six months ended June 30, 2016.
Novavax Second Quarter Achievements:
Announced a new seasonal combination respiratory vaccine program. Novavax demonstrated the ability to combine the RSV F and influenza nanoparticle vaccines, bringing together a vaccine approach that induces broadly neutralizing antibodies against both influenza and RSV. Novavax` program was unveiled at the New Approaches to Vaccines for Human and Veterinary Tropical Diseases Keystone Symposia in Cape Town, South Africa in June 2016.
Continued execution of Resolve(TM), a pivotal Phase 3 trial of our RSV F Vaccine in older adults (60 years of age and older). The Resolve trial is a randomized, observer-blinded, placebo-controlled trial in 11,850 older adults at 60 sites in the United States. The primary efficacy objective is the prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple lower respiratory tract symptoms. Enrollment was completed in the fourth quarter of 2015.
Ongoing execution of a Phase 2 rollover clinical trial of our RSV F Vaccine in 1,330 older adults. The trial is a randomized, observer-blinded, placebo-controlled rollover trial designed to enroll from the population of older adults who participated in the prior Phase 2 trial. The primary endpoints of the trial will evaluate safety and serum anti-F IgG antibody concentrations in response to immunization with our RSV F Vaccine. Enrollment was completed in the fourth quarter of 2015.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Monday session in green amid volatile trading. The shares closed up +1.35 points or 2.69% at $51.56 with 4.64 million shares getting traded. Post opening the session at $50.20, the shares hit an intraday low of $50.15 and an intraday high of $51.7/8 and the price vacillated in this range throughout the day. The company has a market cap of $52.72 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) on September 7, 2016 announced that data on COPAXONE® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (MS), and laquinimod, an investigational therapy for relapsing and primary progressive forms of MS, will be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London, September 14-17, 2016.
“For more than 30 years, Teva has been dedicated to addressing the many unmet needs in MS by investigating new compounds and providing safe and effective treatment options,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We look forward to showcasing new data from our MS portfolio at this year’s ECTRIMS.”
In addition to the data being presented, Teva will also host a Satellite Symposium, “Multiple Disciplines, Common Goals: Just a Minute! Challenge the Expert Panel,” on September 15, 2016 from 6:00 – 7:00 p.m. GMT.